Literature DB >> 23505273

Disseminated Mycobacterium haemophilum infection in a 72-year-old patient with rheumatoid arthritis on infliximab.

C Scott Collins1, Christine Terrell, Paul Mueller.   

Abstract

Mycobacterium haemophilum is a slow growing, aerobic, fastidious mycobacterium requiring hemin and a temperature of 30-32° C for optimal growth that is ubiquitous in nature. Disease in immunocompromised adults typically manifests as skin lesions such as papules, pustules and ulcerations. This organism also causes lymphadenitis in immunocompetent children. Antitumour necrosis factor-α (anti-TNF-α) therapy with agents such as infliximab, etanercept and adalimumab is increasingly being used for immunosuppression in patients with various autoimmune conditions. These agents are known to place patients at increased risk for tuberculosis and other granulomatous diseases. However, little is known about illness caused by M haemophilum in patients on immunosuppression with anti-TNF-α therapy. We describe a case of disseminated M haemophilum manifesting as skin lesions in a 72-year-old man with rheumatoid arthritis on infliximab and methotrexate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23505273      PMCID: PMC3618757          DOI: 10.1136/bcr-2012-008034

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Mycobacterium haemophilum in immunocompromised patients.

Authors:  M K Shah; A Sebti; T E Kiehn; S A Massarella; K A Sepkowitz
Journal:  Clin Infect Dis       Date:  2001-06-21       Impact factor: 9.079

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Disseminated Mycobacterium haemophilum infection.

Authors:  Colleen F Kelley; Wendy S Armstrong; Molly E Eaton
Journal:  Lancet Infect Dis       Date:  2011-07       Impact factor: 25.071

Review 4.  Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.

Authors:  M A Saubolle; T E Kiehn; M H White; M F Rudinsky; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 5.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 6.  Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

Authors:  Kevin L Winthrop; Eric Chang; Shellie Yamashita; Michael F Iademarco; Philip A LoBue
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

7.  Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists.

Authors:  Reinout M Swart; Jakko van Ingen; Dick van Soolingen; Rob Slingerland; Willem D H Hendriks; Jan G den Hollander
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

  7 in total
  3 in total

1.  Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Fung-Chang Sung; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

2.  The Complete Genome Sequence of the Emerging Pathogen Mycobacterium haemophilum Explains Its Unique Culture Requirements.

Authors:  JoAnn M Tufariello; Christopher A Kerantzas; Catherine Vilchèze; R Brent Calder; Eric K Nordberg; Jack A Fischer; Travis E Hartman; Eva Yang; Timothy Driscoll; Laura E Cole; Robert Sebra; Shahina B Maqbool; Alice R Wattam; William R Jacobs
Journal:  mBio       Date:  2015-11-17       Impact factor: 7.867

3.  Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum.

Authors:  Pornboonya Nookeu; Nasikarn Angkasekwinai; Suporn Foongladda; Pakpoom Phoompoung
Journal:  Emerg Infect Dis       Date:  2019-09       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.